Urology

1. Bone mineral density testing was associated with a significant decreased risk of developing major osteoporotic fractures among older men...

1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor inhibitor, in addition to standard therapy demonstrated longer overall survival...

1. Olaparib led to a bigger decrease in pain interference and symptomatic skeletal-related events than hormonal drugs. 2. Olaparib demonstrated...

1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to...

1. In this retrospective cohort study, there was no significant difference in all-cause mortality between patients with prostate cancer and...

1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan,...

1. Magnetic resonance imaging with targeted and standard biopsy was non-inferior for the detection of clinically significant cancers compared to...

1. A double-blinded, randomized controlled trial found that there were no significant differences between afebrile men treated for 7 days...

1. Ipatasertib-abiraterone treatment significantly improved progression-free survival compared to placebo-abiraterone in patients with PTEN-loss metastatic castration-resistant prostate cancer. 2. Grade...

1. Among patients with high-risk prostate cancer receiving guideline-concordant multimodal therapy, prostate cancer-specific mortality outcomes were equivalent among radical prostatectomy,...